Why is Concord Biotech falling/rising?

As of 26-Jun, Concord Biotech Ltd is experiencing a decline in its stock price, currently at 1,795.75, reflecting a decrease of 23.1 points or 1.27%. The stock has underperformed its sector today by 1.35%, and its delivery volume has decreased significantly, falling by 31.61% against the 5-day average. Over the past week, the stock has seen a notable drop of 8.62%, while its performance over the last month shows a gain of 16.61%. Despite a strong long-term fundamental strength characterized by an average Return on Equity (ROE) of 20.62% and healthy growth in operating profit, the recent price movement indicates a struggle, particularly in the short term.
Broader market context reveals that while Concord Biotech has generated a return of 20.31% over the past year, significantly outperforming the market's 4.11%, its recent performance contrasts sharply with the Sensex, which has risen by 2.94% in the last week. The stock's current price movement may be influenced by a combination of falling investor participation and mixed performance relative to its moving averages. Additionally, while institutional investors have increased their stake, indicating confidence in the company's long-term prospects, the immediate market sentiment appears to be cautious, contributing to the stock's decline.